Efpeglenatide Improves Renal, Cardiovascular Outcomes in High-Risk Diabetes
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
Diagnosis & Disease Information
Kidney Function Declines More Slowly With SGLT2 Inhibitor
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
SGLT2 Inhibitors, MRA Compared for Diabetic Kidney Disease
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Underuse of Diabetic Kidney Disease Therapies Reported
Study findings highlight an “unmet need” for newer therapies.
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Medtronic’s SCS Therapy Approved for Painful Diabetic Peripheral Neuropathy
These SCS devices were cleared based on data from a randomized controlled trial published in the journal Diabetes Care in 2014.
Finerenone Provides CV, Renal Benefits in Diabetes Across CKD Spectrum
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
ADA: Efpeglenatide Lowers Risk for Adverse CV Events in T2DM
Findings among patients with type 2 diabetes and history of cardiovascular disease or current kidney disease
